collection
https://read.qxmd.com/read/25268211/-current-treatment-concepts-for-castration-resistant-prostate-cancer
#41
REVIEW
G von Amsberg, P Stroelin, C Bokemeyer, T Steuber
Metastasized castration-resistant prostate cancer (mCRPC) is defined by disease progression despite androgen depletion therapy (ADT). While until recently a life-prolonging effect could only be demonstrated for the taxane docetaxel, various alternative therapeutic options based on different mechanisms of action are available today: CYP17-inhibitor abiraterone and antiandrogen enzalutamide target the androgen receptor-signaling pathway, which maintains a crucial role in mCRPC. Cabazitxel - a semisynthetic taxane derivate - is the only second line chemotherapy, which results in a prolongation of overall survival to date...
October 2014: Deutsche Medizinische Wochenschrift
https://read.qxmd.com/read/25243101/radium-223-dichloride-bone-targeted-alpha-particle-therapy-for-hormone-refractory-breast-cancer-metastatic-to-bone
#42
JOURNAL ARTICLE
Amol Takalkar, Scott Adams, Vivek Subbiah
BACKGROUND: Hormone-refractory breast cancer metastatic to bone is a clinically challenging disease associated with high morbidity, poor prognosis, and impaired quality of life owing to pain and skeletal-related events. In a preclinical study using a mouse model of breast cancer and bone metastases, Ra-223 dichloride was incorporated into bone matrix and inhibited proliferation of breast cancer cells and differentiation of osteoblasts and osteoclasts (all P values < .001) in vitro...
2014: Experimental Hematology & Oncology
https://read.qxmd.com/read/25232039/bone-targeting-radiopharmaceuticals-for-the-treatment-of-bone-metastatic-castration-resistant-prostate-cancer-exploring-the-implications-of-new-data
#43
REVIEW
Charles J Ryan, Philip J Saylor, Jason J Everly, Oliver Sartor
BACKGROUND: Clinical features of patients with castration-resistant prostate cancer (CRPC) are characterized by a high incidence of bone metastases, which are associated with impairment of quality of life, pain, skeletal-related events (SREs), and a negative impact on prognosis. Advances in the understanding of cancer cell-bone stroma interactions and molecular mechanisms have recently permitted the development of new agents. PURPOSE: We review the merits, applications, and limitations of emerging data sets on bone-metastatic CRPC with a focus on radium-223, an α-emitting radiopharmaceutical, and its use in therapy for this disease...
October 2014: Oncologist
https://read.qxmd.com/read/25071888/clinical-use-of-bone-targeting-radiopharmaceuticals-with-focus-on-alpha-emitters
#44
REVIEW
Hinrich A Wieder, Michael Lassmann, Martin S Allen-Auerbach, Johannes Czernin, Ken Herrmann
Various single or multi-modality therapeutic options are available to treat pain of bone metastasis in patients with prostate cancer. Different radionuclides that emit β-rays such as (153)Samarium and (89)Strontium and achieve palliation are commercially available. In contrast to β-emitters, (223)Radium as a α-emitter has a short path-length. The advantage of the α-emitter is thus a highly localized biological effect that is caused by radiation induced DNA double-strand breaks and subsequent cell killing and/or limited effectiveness of cellular repair mechanisms...
July 28, 2014: World Journal of Radiology
https://read.qxmd.com/read/24924181/bone-seeking-radiopharmaceuticals-as-targeted-agents-of-osteosarcoma-samarium-153-edtmp-and-radium-223
#45
REVIEW
Peter M Anderson, Vivek Subbiah, Eric Rohren
Osteosarcoma is a cancer characterized by formation of bone by malignant cells. Routine bone scan imaging with Tc-99m-MDP is done at diagnosis to evaluate primary tumor uptake and check for bone metastases. At time of relapse the Tc-99m-MDP bone scan also provides a specific means to assess formation of bone by malignant osteosarcoma cells and the potential for bone-seeking radiopharmaceuticals to deliver radioactivity directly into osteoblastic osteosarcoma lesions. This chapter will review and compare a bone-seeking radiopharmaceutical that emits beta-particles, samarium-153-EDTMP, with an alpha-particle emitter, radium-223...
2014: Advances in Experimental Medicine and Biology
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.